Business Wire

CA-ADVA

24.1.2023 18:01:38 CET | Business Wire | Press release

Share
Brandywine Communications partners with ADVA to provide a defense-grade M-Code solution with advanced timing

ADVA (FSE: ADV) today announced that Brandywine Communications is using its OSA 5422 grandmaster clock to deliver a robust and feature-rich M-Code timing solution for use cases such as US Department of Defense applications. The new edge synchronization offering addresses the key requirements of military networks by providing enhanced positioning, navigation and timing (PNT) capabilities and improved resilience. Built on Oscilloquartz’s versatile timing technology with integrated M-Code capabilities, the solution is ideal for the most demanding military edge applications. It supports 1Gbit/s and 10Gbit/s interfaces, provides innovative GNSS assurance capabilities as well as backup through Oscilloquartz’s assured PNT (aPNT+) technology, and meets the most stringent timing demands in an operationally efficient and cost-effective way.

“Our M-Code edge timing offering will be a game-changer for defense applications. Powered by ADVA’s OSA 5422 grandmaster clock, it meets the most urgent needs of military networks that require precise and reliable PNT information and delivers new levels of reliability and security. One key feature of the OSA 5422 is its long holdover and PTP backup, which enables it to maintain accurate timing even in the event of M-Code disruption. This is critical for pressurized defense networks that need to operate in a variety of difficult environments,” said Allen Ronk, president of Brandywine Communications. “Our solution features multi-source backup capabilities to ensure that M-Code outages do not disrupt synchronization. It also provides sync assurance capabilities that continually monitor the performance of the timing system and take immediate corrective action when needed.”

M-Code is an encrypted GPS signal used exclusively by the US military in defense applications that require precise and reliable synchronization. Resistant to jamming and spoofing, M-Code is an invaluable asset for defense organizations operating in challenging conditions. ADVA’s OSA 5422 grandmaster clock is now integrated with a highly reliable M-Code receiver that meets stringent frequency and phase synchronization needs and offers the best holdover performance of any edge device on the market. Also equipped with multi-band, multi-constellation GNSS receivers for when M-Code is not available, the device offers support for legacy interfaces such as BITS and IRIG, and features eight field-upgradeable 10Gbit/s ports and 1Gbit/s interfaces. The OSA 5422 is also environmentally hardened with hot-swappable modules and power supplies for easy field upgrades.

“As military applications demand increasingly precise and reliable PNT capabilities, the need for secure, jamming- and spoofing-resistant M-Code technology becomes ever more pressing. With its long holdover, multi-source backup capabilities, sync assurance capabilities, and other advanced features, our OSA 5422 is perfectly positioned to meet this demand,” commented Gil Biran, GM of Oscilloquartz, ADVA. “We’re excited to be working with Brandywine Communications as our strategic partner and to be bringing our innovation to defense applications that rely on precise and reliable PNT in the US and elsewhere. The market for military GPS receivers with M-Code capabilities is growing, as defense organizations seek to enhance their PNT capabilities and improve resilience. Together, we’re helping empower a whole new section of customers to benefit from the industry’s most agile synchronization toolkit.”

ADVA’s Oscilloquartz aPNT+ and M-Code technology is being showcased at the Precise Time and Time Interval Systems and Applications Meeting (PTTI 2023) in Long Beach, California, from January 23 to 26. Attendees can visit the Oscilloquartz team at Brandywine Communications’ booth to learn about the platform’s ability to provide resilient and assured PNT services for military applications in line with the Department of Defense’s latest zero-trust strategy, and how the OSA 5422 supports both time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS).

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005723/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye